The management of soft tissue sarcoma remains problematic despite advances in surgery, radiotherapy, and chemotherapy. Fifty percent of patients still develop distant metastasis and will eventually die from this disease. Presently, the grade and size of the sarcoma are the most important factors used to estimate risk of relapse and overall survival. Assigning a pathologic grade to an individual sarcoma as a means of predicting clinical behavior is often difficult with a 40% discordance rate even between expert sarcoma pathologists. In addition, within each grade it remains difficult to identify those patients at highest risk for distant relapse. Although neoadjuvant chemotherapy is now given for large, high grade extremity and truncal sarcoma it remains difficult to identify those patients unlikely to respond to such therapy at an early enough time point in their treatment course to avoid the toxicity of such therapy. There is mounting evidence that the composition of membrane phospholipid in tumor tissue is an important indicator of a tumor's cellularity and proliferative capacity as well as an important early marker for tumor cell death. However, there is a lack of information on the biochemical determinants of sarcoma proliferation, metastasis and response to therapy. To address these problems novel quantitative ex-vivo NMR methods will be utilized to determine the biochemical changes in tissue lipid and cholesterol for soft tissue sarcoma and therefore predict sarcoma cellularity, necrosis, growth rate, differentiation, metastasis and response to therapy. The specific objectives are: (1) Improve lipid analysis of ex-vivo human sarcoma tissue. (2) Provide an objective measure of human sarcoma tissue cellularity and the percentage of cells in synthesis phase of the cell cycle. (3) Provide an objective measure of human sarcoma microscopic necrosis. (4) Provide an objective measure of sarcoma apoptotic and non-apoptotic cell death in transformed fibroblasts in-vitro. (5) Predict the response to neoadjuvant chemotherapy in human soft tissue sarcoma. (6) Create a novel objective biochemical NMR grading system that is more reproducible and prognostic for survival than the conventional FNCLCC histologic grading system. The results of the proposed investigation will permit the development of a clinically relevant biochemical system of prognostic determinants for soft tissue sarcoma which is currently unavailable. Utilizing this system the treating physician would have a more accurate assessment of prognosis and an improved ability to select patients for adjuvant therapy that are at highest risk of relapse and are most likely to respond to such therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA075720-01A1
Application #
2694997
Study Section
Special Emphasis Panel (ZRG2-ET-2 (03))
Program Officer
Lively, Tracy (LUGO)
Project Start
1998-09-30
Project End
2000-09-30
Budget Start
1998-09-30
Budget End
1999-09-29
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Chen, Jin-Hong; Enloe, Brian M; Xiao, Yong et al. (2003) Isotropic susceptibility shift under MAS: the origin of the split water resonances in 1H MAS NMR spectra of cell suspensions. Magn Reson Med 50:515-21
Chen, Jin-Hong; Enloe, Brian M; Weybright, Patrick et al. (2002) Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med 48:602-10
Chen, J H; Enloe, B M; Fletcher, C D et al. (2001) Biochemical analysis using high-resolution magic angle spinning NMR spectroscopy distinguishes lipoma-like well-differentiated liposarcoma from normal fat. J Am Chem Soc 123:9200-1
Esnaola, N F; Rubin, B P; Baldini, E H et al. (2001) Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 234:215-23
Demetri, G D; Fletcher, C D; Mueller, E et al. (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96:3951-6
Millis, K; Weybright, P; Campbell, N et al. (1999) Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med 41:257-67